

Modul 1: Administrative Documents



C001

1.0 Cover Letter



C002

1.2 Forms



C003

1.2.2.26 GCP Inspections



C237

1.2.2.99 Other Forms



C027

1.2.3 Annexes - Documents on Drug Product Quality



C051

1.2.3.1 DMF Letter of Access



C052

1.2.3.2 Ph. Eur. Certificate of Suitability for Active Substance



C053

1.2.3.3 Ph. Eur. Certificate of Suitability for TSE



C054

1.2.3.4 EMA Certificate for Plasma Master File (PMF)



C055

1.2.3.5 EMA Certificate for Vaccine Antigen Master File (VAMF)



C056

1.2.4 Annexes – Manufacturing



C057

1.2.4.1 GMP Certificate or Other GMP Documents



C058

1.2.4.2 Documentation Concerning Manufacturing Authorisation



C059

1.2.4.3 Complete Manufacturing Information with Flow Chart



C060

1.2.4.4 Confirmation on GMP Conformity



C061

1.2.5 Annexes – Others



C062

1.2.5.1 Comparison of Approved Information for Professionals with EU SmPC (for PSURs)



C063

1.2.5.2 Company Core Data Sheet (for PSURs)



C064

1.3 Product Information and Packaging Material



C029

1.3.1 Information for Professionals



C030

1.3.2 Information for Patients



C031

1.3.3 Packaging Material



C032

1.3.4 Information for Professionals From Other Countries



C033

1.4 Information About the Expert



C034

1.4.1 Quality



C035

1.4.2 Nonclinical



C036

1.4.3 Clinical



C037

1.5 Data of Bioavailability Studies



C038

1.6 Environmental Risk Assessment



C039

1.7 Decision of Foreign Authorities



C040

1.7.1 Responses to LoQ



C041

1.7.2 Assessment Report



C042

1.7.3 EU Decision



C043

1.7.4 FDA Decision



C044

1.7.5 Decision of Other Foreign Authorities



C045

1.7.6 Paragraph 13 Additional Documentation



C046

1.7.6 Article 13 Additional Documentation



CC46

1.8 Information Relating to Pharmacovigilance



C047

1.8.1 Pharmacovigilance System



C048

1.8.2 Risk Management System



C049

1.9 Fast Track Status Decision



CA65

1.10 Information Relating to Paediatrics



C050

1.11 Orphan Drug Status Decision



CB65

1.12 Art 14 Sec 1 Let abis-quater TPA



C238

Additional Information



C065

Responses to Swissmedic LoQ



C066

Modul 2: Common Technical Document Summaries



C068

2.1 Common Technical Document Table of Contents (Modules 2-5)



C069

2.2 CTD Introduction



C070

2.3 Quality Overall Summary



C071

2.3 Introduction



C072

2.3.S Drug Substance



C073

2.3.P Drug Product



C074

2.3.A Appendices



C075

2.3.R Regional Information



C076

2.4 Nonclinical Overview



C077

2.5 Clinical Overview



C078

2.6 Nonclinical Written and Tabulated Summaries



C079

2.6.1 Introduction



C080

2.6.2 Pharmacology Tabulated Summaries



C081

2.6.3 Pharmacology Written Summaries



C082

2.6.4 Pharmacokinetics Tabulated Summaries



C083

2.6.5 Pharmacokinetics Written Summaries



C084

2.6.6 Toxicology Tabulated Summaries



C085

2.6.7 Toxicology Written Summaries



C086

2.7 Clinical Summary



C087

2.7.1 Biopharmaceutic Studies and Associated Analytical Methods



C088

2.7.2 Clinical Pharmacology Studies



C089

2.7.3 Clinical Efficacy



C090

2.7.4 Clinical Safety



C091

2.7.5 Literature References



C092

2.7.6 Synopses of Individual Studies



C093

Modul 3: Quality



C094

3.1 Table of Contents of Module 3



C095

3.2 Body of Data



C096

3.2.S Drug Substance



C097

3.2.S.1 General Information



C098

3.2.S.11 Nomenclature



C099

3.2.S.12 Structure



C100

3.2.S.13 General Properties



C101

3.2.S.2 Manufacture



C102

3.2.S.2.1 Manufacturer(s)



C103

3.2.S.2.2 Description of Manufacturing Process and Process Controls



C104

3.2.S.2.3 Control of Materials



C105

3.2.S.2.4 Controls of Critical Steps and Intermediates



C106

3.2.S.2.5 Process Validation and/or Evaluation



C107

3.2.S.2.6 Manufacturing Process Development



C108

3.2.S.3 Characterisation



C109

3.2.S.3.1 Elucidation of Structure and Other Characteristics



C110

3.2.S.3.2 Impurities



C111

3.2.S.4 Control of Drug Substance



C112

3.2.S.4.1 Specification



C113

3.2.S.4.2 Analytical Procedures



C114

3.2.S.4.3 Validation of Analytical Procedures



C115

3.2.S.4.4 Batch Analyses



C116

3.2.S.4.5 Justification of Specification



C117

3.2.S.5 Reference Standards or Materials



C118

3.2.S.6 Container Closure System



C119

3.2.S.7 Stability



C120

3.2.S.7.1 Stability Summary and Conclusions



C121

3.2.S.7.2 Post-approval Stability Protocol and Stability Commitment



C122

3.2.S.7.3 Stability Data



C123

3.2.P Drug Product



C124

3.2.P.1 Description and Composition of the Drug Product



C125

3.2.P.2 Pharmaceutical Development



C126

3.2.P.2.1 Components



C127

3.2.P.2.2 Product



C128

3.2.P.2.3 Process



C129

3.2.P.2.4 Container



C130

3.2.P.2.5 Microbiology



C131

3.2.P.2.6 Compatibility



C132

3.2.P.3 Manufacture



C133

3.2.P.3.1 Manufacturer(s)



C134

3.2.P.3.2 Batch Formula



C135

3.2.P.3.3 Description of Manufacturing Process and Process Controls



C136

3.2.P.3.4 Controls of Critical Steps and Intermediates



C137

3.2.P.3.5 Process Validation and/or Evaluation



C138

3.2.P.4 Control of Exipients



C139

3.2.P.4.1 Specifications



C140

3.2.P.4.2 Analytical Procedures



C141

3.2.P.4.3 Validation of Analytical Procedures



C142

3.2.P.4.4 Justification of Specifications



C143

3.2.P.4.5 Excipients of Human or Animal Origin



C144

3.2.P.4.6 Novel Excipients



C145

3.2.P.5 Control of the Drug Product



C146

3.2.P.5.1 Specification(s)



C147

3.2.P.5.2 Analytical Procedures



C148

3.2.P.5.3 Validation of Analytical Procedures



C149

3.2.P.5.4 Batch Analyses



C150

3.2.P.5.5 Characterisation of Impurities



C151

3.2.P.5.6 Justification of Specifications



C152

3.2.P.6 Reference Standards or Materials



C153

3.2.P.7 Container Closure Systems



C154

3.2.P.8 Stability



C155

3.2.P.8.1 Stability Summary and Conclusion



C156

3.2.P.8.2 Post-approval Stability Protocol and Stability Commitment



C157

3.2.P.8.3 Stability Data



C158

3.2.A Appendices



C159

3.2.R Regional Information



C160

3.3 Literature References



C161

Modul 4: Nonclinical Study Reports



C162

4.1 Table of Contents of Module 4



C163

4.2 Study Reports



C164

4.2.1 Pharmacology



C165

4.2.1.1 Primary Pharmacodynamics



C166

4.2.1.2 Secondary Pharmacodynamics



C167

4.2.1.3 Safety Pharmacology



C168

4.2.1.4 Pharmacodynamic Drug Interactions



C169

4.2.2 Pharmacokinetics



C170

4.2.2.1 Analytical Methods and Validation Reports



C171

4.2.2.2 Absorption



C172

4.2.2.3 Distribution



C173

4.2.2.4 Metabolism



C174

4.2.2.5 Excretion



C175

4.2.2.6 Pharmacokinetic Drug Interactions (Nonclinical)



C176

4.2.2.7 Other Pharmacokinetic Studies



C177

4.2.3 Toxicology



C178

4.2.3.1 Single-Dose Toxicity



C179

4.2.3.2 Repeat-Dose Toxicity



C180

4.2.3.3 Genotoxicity



C181

4.2.3.3.1 In Vitro



C182

4.2.3.3.2 In Vivo



C183

4.2.3.4 Carcinogenicity



C184

4.2.3.4.1 Long-Term Studies



C185

4.2.3.4.2 Short- or Medium-Term Studies



C186

4.2.3.4.3 Other Studies



C187

4.2.3.5 Reproductive and Developmental Toxicity



C188

4.2.3.5.1 Fertility and Early Embryonic Development



C189

4.2.3.5.2 Embryo-fetal Development



C190

4.2.3.5.3 Prenatal and Postnatal Development, Including Maternal Function



C191

4.2.3.5.4 Studies in which the Offspring (Juvenile Animals) Are Dosed and/or Further Evaluated



C192

4.2.3.6 Local Tolerance



C193

4.2.3.7 Other Toxicity Studies



C194

4.2.3.7.1 Antigenicity



C195

4.2.3.7.2 Immunotoxicity



C196

4.2.3.7.3 Mechanistic studies



C197

4.2.3.7.4 Dependence



C198

4.2.3.7.5 Metabolites



C199

4.2.3.7.6 Impurities



C200

4.2.3.7.7 Other



C201

4.3 Literature References



C202

Modul 5: Clinical Study Reports



C203

5.1 Table of Contents of Module 5



C204

5.2 Tabular Listing of All Clinical Studies



C205

5.3 Clinical Study Reports



C206

5.3.1 Reports of Biopharmaceutic Studies



C207

5.3.1.1 Bioavailability (BA) Study Reports



C208

5.3.1.2 Comparative BA and Bioequivalence (BE)



C209

5.3.1.3 In Vitro – In Vivo Correlation Study Reports



C210

5.3.1.4 Reports of Bioanalytical and Analytical Methods for Human Studies



C211

5.3.2 Reports of Studies Pertinent to PK Using Human Biomaterials



C212

5.3.2.1 Plasma Protein Binding Study Reports



C213

5.3.2.2 Reports of Hepatic Metabolism and Drug



C214

5.3.2.3 Reports of Studies Using Other Human Biomaterials



C215

5.3.3 Reports of PK Studies



C216

5.3.3.1 Healthy Subject PK and Initial Tolerability



C217

5.3.3.2 Patient PK and Initial Tolerability Study



C218

5.3.3.3 Intrinsic Factor PK Study Reports



C219

5.3.3.4 Extrinsic Factor PK Study Reports



C220

5.3.3.5 Population PK Study Reports



C221

5.3.4 Reports of PD Studies



C222

5.3.4.1 Healthy Subject PD and PK/PD Study Reports



C223

5.3.4.2 Patient PD and PK/PD Study Reports



C224

5.3.5 Reports of Efficacy and Safety Studies



C225

5.3.5.1 Study Reports of Controlled Clinical Studies Pertinent to the Claimed Indication



C226

5.3.5.2 Study Reports of Uncontrolled Clinical Studies



C227

5.3.5.3 Reports of Analyses of Data from More Than One Study



C228

5.3.5.4 Other Study Reports



C229

5.3.6 Reports of Postmarketing Experience



C230

5.3.7 Case Report Forms and Individual Patient Listings



C231

5.4 Literature References



C232